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نتائج احلمل يف النساء املصابات بأنيميا البحر املتوسط بيتا الثالسيميا
خربة مركز واحد يف ُعمان
نهال الريامية، مها اخل�سورية، �ساهينا داعر
abstract: Objectives: Pregnancy in women with homozygous beta thalassaemia (HBT) carries a high risk to 
both the mother and fetus. The aim of this study was to investigate pregnancy outcomes among this group at a 
single tertiary centre. Methods: This retrospective descriptive study was conducted between January 2006 and 
December 2012 on all women with HBT who received prenatal care and subsequently delivered at Sultan Qaboos 
University Hospital, Muscat, Oman. Women who delivered elsewhere and women with the beta thalassaemia trait 
were excluded. Results: Ten women with HBT were studied with a total of 15 pregnancies and 14 live births. The 
mean maternal age ± standard deviation (SD) was 27.9 ± 3.7 years, with a range of 24‒35 years. There were 14 
spontaneous pregnancies and one pregnancy following hormone treatment. Eight women had been on chelation 
therapy before pregnancy, one of whom needed chelation during late pregnancy. Of the pregnancies, 93% had a 
successful outcome with a mean ± SD gestational age at delivery of 38.6 ± 0.9 weeks, with a range of 37‒40 weeks. 
Eight babies (57%) were delivered by Caesarean section. The mean ± SD birth weight was 2.6 ± 0.2 kg, with a 
range of 1.9‒3.0 kg. Three babies (21%) were born with low birth weights. Conclusion: Pregnancy is safe and 
usually has a favourable outcome in patients with HBT, provided that a multidisciplinary team is available. This is 
the first study of Omani patients with HBT whose pregnancies have resulted in a successful outcome.
Keywords: Thalassemia, beta; Pregnancy; Fetus; Mother; Assessment, Patient Outcomes; Chelation Therapy; Oman.
هدفت  واجلنني.  الأم  من  كل  على  عالية  خماطر  على  الثال�سيميا  بيتا  مبر�س  امل�سابات  الن�ساء  يف  احلمل  ينطوي  الهدف:  امللخ�ص: 
بني  الو�سفية  الإ�ستعادية  الدرا�سة  هذه  اأجريت  الطريقة:  واحد.  مركز  يف  املري�سات  من  املجموعة  هذه  يف  احلمل  نتائج  ر�سد  اإىل  الدرا�سة 
م�ست�سفى  يف  و�سعن  و  الولدة  قبل  الرعاية  تلقوا  الذين  ثال�سيميا  بالبيتا  امل�سابات  الن�ساء  جميع  على   2012 دي�سمرب  و   2006 يناير 
ثال�سيميا البيتا  �سفة  حامالت  والن�ساء  اأخرى  اأماكن  يف  و�سعن  الالئي  الن�ساء  ا�ستبعاد  مت  عمان.  �سلطنة  م�سقط،  قابو�س،  ال�سلطان   جامعة 
النتائج: در�ست ع�رس ن�ساء م�سابات بالبيتا الثال�سيميا حيث حدث 15 حمال اأ�سفرت عن 14 ولدة حية. بلغ متو�سط عمر الأمهات يف عينة 
الدرا�سة 3.7 ± 27.9 وتراوحت اعمارهن بني 35-24 عاما. كان هناك 14 حالة حمل عفوي وحالة واحدة بعد العالج الهرموين. تعاطت 
ثمانية ن�ساء عقاقري اإزالة معدن احلديد من اجل�سم قبل احلمل بينما تعاطت حالة واحدة فقط هذه العقاقري يف اأواخر احلمل. اأ�سفرت %93 من 
الولدات عن نتيجة ناجحة وبلغت فرتة حمل اجلنني من 0.9 ± 38.6 اأ�سابيع يف املتو�سط، وتراوحت فرتة احلمل بني 40-37 اأ�سبوعا. ولد 
ثمانية اأطفال )%57( بعمليات قي�رسية.بلغ متو�سط وزن الطفل عند الولدة  0.2 ± 2.6 كلغ وتراوحت اأوزانهم بني 3.0-1.9 كلغ. كان وزن 
الولدة منخف�سا يف ثالثة اأطفال فقط )%21(. اخلال�صة: اأظهرت هذه الدرا�سة نتائج اإيجابية للحمل و اأمان يف امل�سابات بالبيتا ثال�سيميا، 
�رسيطة اأن يكونوا حتت رعاية فريق متعدد من املتخ�س�سني. هذه هي الدرا�سة الأوىل يف املر�سى العمانيني.
مفتاح الكلمات: الثال�سيميا، بيتا؛ احلمل؛ اجلنني؛ الأم؛ تقييم، النتائج ؛ عقاقري اإزالة معدن احلديد من اجل�سم؛ عمان.
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Advances in Knowledge
- Thalassaemia is not well-studied during pregnancy, especially in Oman. However, thalassaemia is an important blood disorder in 
Oman and carries major risks during pregnancy to both the mother and fetus. The results of this study will increase knowledge of this 
disorder in the region.
- Specifically, the findings of this study will increase the awareness of the safe outcomes of pregnancies in women with homozygous beta 
thalassaemia in Oman, especially for healthcare professionals.
Application to Patient Care
- This study highlights certain issues in pregnant women with homozygous thalassaemia, which will help obstetricians in their 
management of this patient group. 
- Recent advances in the treatment and management of thalassaemic patients are discussed in this study.
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Beta thalassaemia is one of the most common genetic blood disorders in Oman, the Mediterranean region, Arabian Peninsula 
and Far East. The prevalence of the beta thalassaemia 
gene in Oman is reported to be 2.2‒2.6%.1,2 Patients 
with homozygous beta thalassaemia (HBT) have high 
morbidity and mortality rates due to the consequences 
of blood transfusions and iron overload. Two forms of 
thalassaemia are distinguished, with different clinical 
phenotypes: thalassaemia major (TM), which is 
transfusion-dependent, and thalassaemia intermedia 
(TI), which varies in clinical severity and has variable 
transfusion requirements.
In recent years, TM survival rates have improved 
with patients suffering fewer complications due to 
the advances in transfusion treatment and the use of 
chelation therapy.3‒6 As a consequence, pregnancy is 
feasible in these patients. The main cause of infertility 
in TM is due to pituitary gland haemosiderosis 
leading to hypogonadotropic hypogonadism.7,8 TI 
has a wide clinical spectrum ranging from patients 
presenting late, after the age of three years, and then 
requiring regular blood transfusions, to those who are 
completely transfusion-independent. The latter group 
requires occasional transfusions during periods of 
stress such as pregnancy and infection, as well as pre-
operatively.
Patients with HBT require close follow-up 
throughout the duration of their pregnancy due to the 
physiological changes and high demands of pregnancy.9 
Chelation therapy should be halted during pregnancy 
due to the teratogenicity of this treatment and 
haemoglobin (Hb) levels should be checked regularly 
to assess the need for transfusions. An increased 
frequency of blood transfusions is usually noted in 
these patients. Complications for both the mother and 
the fetus include gestational hypertension, gestational 
diabetes, thromboembolism, anaemia, cardiac failure, 
premature delivery, intrauterine growth restriction 
and fetal death.10
The aim of this study was to review the maternal 
and fetal outcomes of pregnant women with HBT at 
Sultan Qaboos University Hospital (SQUH), Muscat, 
Oman.
Methods
This retrospective descriptive study was conducted 
between January 2006 and December 2012 on all 
pregnant women with HBT who received both prenatal 
and postnatal care and delivered at SQUH. Data were 
obtained from the SQUH database including the 
patients’ medical and delivery ward records.
Women who delivered elsewhere and women 
with the beta thalassaemia trait were excluded from 
the study. A total of 10 women (seven with TI and 
three with TM) were included giving a total of 15 
pregnancies. The patients were followed closely in 
the SQUH high-risk pregnancy clinic by both an 
obstetrician and a haematologist. They were screened 
for infectious diseases upon presentation, including 
hepatitis B, syphilis and human immunodeficiency 
virus (HIV). An obstetric ultrasound was performed 
to confirm gestational age. Maternal weight gain, 
blood pressure and fetal well-being were assessed 
at each visit. A fetal anatomy scan was performed 
at 18‒20 gestational weeks and fetal growth scans 
were performed monthly. Patients received blood 
transfusions approximately every two to three weeks 
to maintain Hb levels above 9.0 g/dL. The maternal 
medical records were reviewed for age, parity, use of 
fertility-inducing agents, any history of splenectomy, 
baseline Hb levels at first visit as well as at delivery, 
frequency of blood transfusions, serum ferritin levels 
and the use of chelation therapy during pregnancy.
Pregnancy outcomes were defined as follows: an 
abortion was defined as a pregnancy loss before 20 
weeks’ gestation;11 intrauterine fetal death was defined 
as the death of the fetus in utero after 20 weeks’ 
gestation;11 preterm delivery was defined as a delivery 
before 37 weeks’ gestation;11 fetal growth restriction 
was recorded if the estimated fetal weight was less 
than the 10th percentile;12 low birth weight (LBW) was 
defined as a birth weight of less than 2,500 g,12 and the 
mode of delivery was recorded as either vaginal delivery 
or a Caesarean section. Maternal complications were 
also recorded, including gestational hypertension, 
gestational diabetes, infections and antepartum and 
postpartum haemorrhaging.
Descriptive data are presented as means, standard 
deviations (SD) and percentages. The study was 
approved by the Medical Research & Ethics Committee 
of the College of Medicine & Health Sciences at Sultan 
Qaboos University.
Results
This study evaluated 15 pregnancies in 10 women 
with HBT. One patient with TM became pregnant 
twice but miscarried during her first pregnancy. Three 
patients with TI had subsequent pregnancies during 
the study period, with one of these patients becoming 
pregnant three times.
The mean maternal age ± SD was 27.9 ± 3.7 
years, with a range of 24‒35 years. Nine women were 
nulliparous at the start of the study. All of the women 
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conceived spontaneously, apart from one of the three 
women with TM, who conceived using hormone 
treatments. In total, four women (40%)—one with 
TM and three with TI—were splenectomised. All 
women required blood transfusions every two to 
three weeks during their pregnancies, including the 
seven patients with TI who had not received regular 
blood transfusions before pregnancy. Eight women 
(80%)—three with TM and five with TI—had been on 
chelation therapy before their pregnancies [Table 1].
The pregnancy outcomes of all patients with TI 
and TM are presented in Table 2. In patients with TI, 
there were 11 live births. The mean ± SD gestational 
age at delivery was 38.6 ± 1.0 weeks with a range of 
37‒40 weeks. Three babies were delivered by elective 
Caesarean section due to a fetal breech presentation in 
two patients and a previous Caesarean section in one 
patient. Two further patients underwent emergency 
Caesarean sections due to fetal distress. The mean 
± SD birth weight was 2.5 ± 0.3 kg, with a range of 
1.9‒3.0 kg.
Three babies were born with LBWs of 1.9, 2.2 and 
2.3 kg. The first baby was born to a 28-year-old gravida 
one para zero (G1P0) woman who had no antepartum 
complications. She had been on regular blood 
transfusions every two weeks during her pregnancy. 
Her lowest Hb level was 6.4 g/dL in the first trimester 
and her highest serum ferritin level was 1,469 ng/mL 
at the end of the pregnancy. Her baby was born by 
vacuum-assisted delivery at 38 weeks’ gestation due to 
a non-reassuring fetal heart rate in the second stage 
of labour. The baby was female with a birth weight 
of 1.9 kg; she demonstrated good Apgar scores and 
therefore did not require admission to the Neonatal 
Intensive Care Unit (NICU). The second baby was 
born to a 30-year-old primigravida woman who had 
no antepartum complications. Her lowest Hb level 
during pregnancy was 8.7 g/dL in the second trimester 
and her highest serum ferritin level was 336 ng/mL at 
the end of the pregnancy. She delivered by emergency 
Caesarean section at 40 weeks’ gestation due to a non-
reassuring fetal heart rate during labour. The baby was 
male, with good Apgar scores and normal pH levels as 
determined by the cord blood gas, indicating normal 
hydrogen ions in the blood. The third baby was born 
to a 30-year-old G1P0 woman whose lowest Hb level 
in pregnancy was 7.5 g/dL in the middle of the first 
trimester and whose highest ferritin level was 1,334 
ng/mL at the end of the pregnancy. She delivered at 37 
weeks’ gestation by elective Caesarean section due to a 
breech presentation; the boy had a birth weight of 2.3 
kg and good Apgar scores.
In patients with beta TM, the mean ± SD 
gestational age was 38.3 ± 0.6 weeks, with a range of 
38‒39 weeks. The mean ± SD birth weight was 2.8 ± 
0.2 kg, with a range of 2.7‒3.0 kg. Two patients had 
elective Caesarean sections, one because of a fetal 
breech presentation and one at the patient’s request. 
The third patient had an emergency Caesarean section 
due to fetal distress.
One patient elected to restart chelation therapy 
during her pregnancy. The patient was a 26-year-old 
primigravida woman who conceived spontaneously 
and was progressing well during pregnancy. Her 
baseline serum ferritin level was 522 ng/mL, however 
this increased throughout her pregnancy and reached 
2,767 ng/mL at 28 weeks’ gestation. After extensive 
counselling, the patient opted for iron chelation with 
Table 1: Maternal characteristics of pregnant women 
with homozygous beta thalassaemia (N = 10)
Characteristics Mean Range
Age in years 27.9 24‒35
Gravidity 2.7 1‒9
Parity 1.1 0‒6
Hb levels during pregnancy in 
gm/dL
8 6.4‒9.8
SF levels before pregnancy in 
ng/mL (normal range 20‒300 
ng/mL)
585.6 236‒1,258
SF levels at the end of 
pregnancy in ng/mL
1,357.5 336‒3,054
Hb = haemoglobin; SF = serum ferritin.
Table 2: Pregnancy outcomes of women with 
homozygous beta thalassaemia* (N = 15 pregnancies) 
Outcomes TI  
patients 








Mean GA at delivery in weeks 38.6 38.3
Mean birth weight in kg 2.5 2.8
C/S 5 3
Vacuum-assisted delivery 2 0
SVD 4 0
Postpartum fever 3 1
TI = thalassaemia intermedia; TM = thalassaemia major; IUGR = 
intrauterine growth restriction; UTI = urinary tract infection; GDM = 
gestational diabetes mellitus; GA = gestational age; C/S = Caesarean 
section; SVD = spontaneous vaginal delivery.
*Only one patient with TM underwent chelation therapy during her 
pregnancy. 
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deferoxamine in the middle of her third trimester. 
Repeat testing of her serum ferritin levels showed 
marked improvement, with a level of 1.536 ng/mL 
by the end of her pregnancy. She had an elective 
Caesarean section at 38 weeks’ gestation and delivered 
a live male baby with a birth weight of 2.7 kg and Apgar 
scores of nine and ten at one and five min, respectively.
All TM women underwent T2* magnetic 
resonance imaging (MRI) before and soon after 
pregnancy to investigate their iron status. All three 
patients, and in particular the first two patients, had 
increased liver iron loads during their pregnancies. 
The third patient had undergone chelation therapy in 
her third trimester, as mentioned above. The cardiac 
iron status of all the three patients remained normal 
[Table 3].
All women were on prophylactic low-molecular-
weight heparin in the postpartum period and were 
encouraged to breastfeed their infants for the first 12 
weeks before restarting chelation therapy.
Discussion
This study found a 93% rate of successful pregnancy 
outcomes among 10 women with homozygous beta 
thalassaemia. Only one patient with TM suffered a 
first trimester abortion. Such excellent results are 
heartening, particularly considering the difficulties that 
are usually expected in these high-risk pregnancies. 
The major contributing factors to this excellent rate 
were the multidisciplinary approach used in the care 
of these patients as well as the close patient follow-up. 
All of the women with TM in this study underwent 
counselling before pregnancy and had achieved low 
serum ferritin levels (236–522 ng/mL) with extensive 
chelation therapy before conception. Patients with 
TI demonstrated slightly higher serum ferritin levels 
of 194‒1,597 ng/mL (median 625 ng/mL). All of the 
women’s partners had been screened and tested for 
haemoglobinopathies prior to their marriage. There 
were no preterm births noted in the current study 
and only three babies (21%) were born with LBWs. 
However, none required admission to the NICU or 
suffered any neonatal complications.
The results of this study are comparable to two 
large studies reported in the literature.13,14 An Italian 
multicentre study by Origa et al. of 57 pregnant 
women reported a 91% rate of successful pregnancy 
outcomes.13 They also noted favourable maternal and 
neonatal outcomes; however, women with TI who were 
not transfused or were on minimal blood transfusions 
before their pregnancies required more transfusions 
due to anaemia during their pregnancies.13 This finding 
was also observed in the current study.
As reported in other studies, the increase in 
blood transfusions, due to the physiological changes 
and increased demands of pregnancy as well as the 
cessation of chelation therapy, resulted in an increased 
iron overload and aggravates haemosiderosis; this 
caused further iron deposits in major organs such 
as the heart, leading to cardiac dysfunction and 
complications.15,16 Due to intensive patient counselling 
and chelation therapy prior to pregnancy, none of the 
patients with TM in the current study developed iron 
overload in their hearts and all had minimal liver iron 
loads before pregnancy. However, an increase in liver 
iron load was apparent in all patients after pregnancy; 
this was expected as the liver is the primary target 
of iron loading secondary to blood transfusion. 
Cardiac iron status measured by T2* MRI showed no 
significant change before or after pregnancy.
Studies have shown that iron loading of the heart 
usually lags behind that of the liver, which is the initial 
site of the transfusional iron uptake.17 As the present 
study’s patients were well-chelated prior to their 
pregnancies, with low liver iron loads, this may have 
ensured that a buffer was present, possibly protecting 
them from accumulating cardiac iron while they ceased 
chelation therapy during pregnancy. The use of iron 
chelation therapy during pregnancy has not been well-
studied; the main concern is that of fetal teratogenicity, 
especially if the therapy is used in the first trimester.18 
However, there have been a few reports of successful 
outcomes with chelation therapy.19,20 One case reported 
the use of chelation therapy during the first trimester 
with a normal outcome for the child.21 The pregnancy 
had not been identified until 22 weeks gestation as 
the patient was on hormone replacement therapy. 
Fortunately, the fetus was healthy. Another case 
reported the use of chelation therapy from 18 weeks 
gestation until delivery, with a successful outcome 
and a normal assessment of the child at 10 months of 
age.20 However, these are aberrant cases, and chelation 
therapy should be avoided during the first trimester. In 
later pregnancy, a multidisciplinary assessment before 
starting chelation is critical and the potential maternal 
Table 3: Liver and cardiac iron status in three patients 





Patient 1 Patient 2 Patient 3
Liver iron in 
mg/g dry weight 
2.9/10.8 2.6/9.6 2.1/3.6
Cardiac T2* MRI 
in ms 
19.7/20.3 34.8/37.4 46.4/46.8
MRI = magnetic resonance imaging; ms = milliseconds.
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benefits should outweigh the risk to the fetus. After 
a detailed multidisciplinary assessment and intensive 
counselling, one of the women with TM in the current 
study was started on chelation therapy during her third 
trimester, resulting in a positive outcome. However, 
more studies are required to determine the safety of 
chelation therapy during pregnancy.15
The mean gestational age of delivery in the 
present study was 38.6 weeks, with Caesarean 
section as the mode of delivery in 8 out of the 
14 term pregnancies (57%). The preferable 
mode of delivery was usually vaginal, however 
one of the patients insisted on a Caesarean 
section despite counselling. Results from Origa 
et al.’s study on 58 pregnancies in 46 women with HBT 
showed a very high rate of Caesarean sections (90%) 
and a joint study from Lebanon and Milan also showed 
a high rate (72.7%).12,22 Compared to other published 
studies, the rate of Caesarian section in the current 
study was relatively low; however, this may be because 
the total number of pregnancies studied was smaller.
Conclusion
Pregnancy is safe and usually has a favourable outcome 
in patients with HBT, provided that a multidisciplinary 
team is available for intensive patient evaluation and 
follow-up. Advances in fertility treatment and chelation 
therapy have made it possible for women with TM 
to become pregnant. Pre-pregnancy counselling and 
assessment, proper care and close follow-up during 
the antepartum, intrapartum and postpartum periods 
are essential for a good outcome. This is the first study 
of Omani patients with HBT showing a high rate of 
successful pregnancy outcomes.
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